Effects of inhibiting protein arginine methyltransferases (PRMTs) on immunomodulatory gene expression using in vitro breast cancer models

Read full text Summarise with VIRAT
Authors: Lorraine Tshegofatso Maebele
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This study investigated the effects of inhibiting protein arginine methyltransferases (PRMTs) on immunomodulatory gene expression using in vitro breast cancer models. Breast cancer cell lines (MDA-MB-231 and MCF-7) and a non-tumorigenic breast cell line (MCF-10A) were treated with different concentrations of PRMT1 or PRMT5 inhibitors, with DMSO used as a control. Cell viability was assessed using the Alamar Blue assay, and a scratch assay was performed to evaluate the migratory potential of MDA-MB-231 cells after treatment. Gene expression levels of cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death protein 1 (PD-1), programmed death ligand 1 (PD-L1), lymphocyte activation gene-3 (LAG-3), and T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) were measured using quantitative PCR (qPCR). The data include cell viability percentages for MDA-MB-231, MCF-7, and MCF-10A cells under the different treatments, scratch assay images of treated MDA-MB-231 cells, RNA quality control results, and comparisons of immunomodulatory gene expression across cell lines and treatments.

Fields of Study & Subjects

Cancer-related gene regulation Cancer Immunotherapy and Biomarkers Polyamine Metabolism and Applications

Publication details

Journal / source
University of Pretoria
Publication date
27 March 2026
Language
EN
Document type
Dataset